Susan Thackwray

Statistics

Publications

Citations

185

H-Index

Active since

2020

Affiliations

Arrowhead Pharmaceuticals (United States)(Current)

Royal Prince Alfred Hospital

Université de Montréal

The University of Western Australia

Baylor College of Medicine

Susan Thackwray is an author at Arrowhead Pharmaceuticals (United States) specializing in clinical pharmacology, pharmacology, and dyslipidemia pharmacotherapy.

Publications per year

2020–2023

Publications

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

Raburn M. Mallory, Neil Formica, Susan Pfeiffer et al. · The Lancet Infectious Diseases · 2022 · 81 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +16

RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia

Daniel Gaudet, Peter Clifton, David Sullivan et al. · NEJM Evidence · 2023 · 69 citations

Medicine, Pharmacokinetics, Pharmacology +17

Abstract 10357: ARO-APOC3, an Investigational RNAi Therapeutic, Shows Similar Efficacy and Safety in Genetically Confirmed FCS and Non-FCS Participants with Severe Hypertriglyceridemia

Peter Clifton, David Sullivan, John E. Baker et al. · Circulation · 2021 · 19 citations

Medicine, Endocrinology, Pharmacology +16

Abstract 12594: Pharmacodynamic Effect of ARO-APOC3, an Investigational Hepatocyte-targeted RNA Interference Therapeutic Targeting Apolipoprotein C3, in Patients With Hypertriglyceridemia and Multifactorial Chylomicronemia

Peter Clifton, David Sullivan, John E. Baker et al. · Circulation · 2020 · 16 citations

Medicine, Pharmacology, Pharmacotherapy +16

1–4 of 4